€354.15
Your prediction
Vertex Pharmaceuticals Inc. Stock
Pros and Cons of Vertex Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Vertex Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc. | 1.300% | -2.551% | 5.955% | -22.095% | -9.909% | 15.915% | 87.856% |
| Regeneron Pharmaceuticals Inc. | 1.050% | -1.217% | 0.392% | -47.532% | -28.016% | -35.689% | -4.921% |
| Exact Sciences | 0.360% | 1.964% | 17.451% | -19.413% | -3.586% | 67.964% | -40.549% |
| Incyte Corp. | 1.310% | 1.909% | 5.626% | 22.572% | 13.694% | 5.210% | -3.413% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When evaluating the financial position of Vertex Pharmaceuticals Inc. (symbol: VRTX), it is evident that the company exhibits robust financial health, especially for a player in the Biotechnology & Medical Research sector. As observed from the provided financial statements, Vertex demonstrates strong revenue growth, impressive profitability, and significant cash reserves. This overall positive trend is accompanied by notable investment in research and development, which is critical for sustaining innovation in the biotech field. However, like any investment, a deeper dive into the various financial metrics is essential to identify both advantages and drawbacks.
Strong Revenue Generation: Vertex reported a total revenue of approximately $9.87 billion for 2023, showcasing healthy growth compared to previous years. The quarterly revenue growth rate of 13.3% indicates consistent demand for its products, which is promising for future sales and market expansion.
Impressive Profit Margins: The profit margin stands at around 39.5%, highlighting Vertex's ability to convert sales into profits effectively. Coupled with an operating margin of 45.2%, it reflects efficient management of operational expenses relative to revenue.
Comments
News
2 Beaten-Down Stocks Primed for a Comeback
Equity markets are said to be forward looking. However, sometimes they fail to look far enough into the future by reacting too harshly to the challenges some companies face in the present. The good
5 Top Stocks to Buy in October
As we enter the final three months of 2025, some investors may be looking for red-hot growth stocks with room to run. Whereas others may be searching for beaten-down stocks at compelling valuations
2 Growth Stocks to Buy and Hold Forever
Investors who bought shares of Intuitive Surgical (NASDAQ: ISRG) or Vertex Pharmaceuticals (NASDAQ: VRTX) 20 years ago and held onto them are likely pleased with their decisions. Both companies have